Furthermore, the heightened Cx43 gap junctional activity induced by αCT1 treatment inhibits the proliferation or survival of breast cancer cells while having no effect on non-transformed MCF10A cells. This evidence concerns the gene TRAF3IP2 and breast carcinoma.